JW Therapeutics - Concerns Are in the Short Term but Still Promising in the Long Term
This article analyzed the concerns (market size, high cost, financial performance, etc.) for JW Therapeutics in the short run but also include...
496 Views
RemeGen IPO: Key Drugs Show Promising Potential
RemeGen is a commercial-ready biopharmaceutical company who has filed for an IPO on the HKEX. In this insight, we explore the company's core drug...
426 Views
RemeGen IPO Initiation: Seeking a Cure
RemeGen currently has a pipeline of more than ten drug candidates. Overall, we believe that the prospectus RemeGenās core drug assets (telitacept,...
352 Views
JW Therapeutics: Limited Upside from the Top End; Further Potential if Other Drugs Become Successful
In this insight, we take a look at the companyās drug candidates, core product relma-cel and its potential and the attractiveness of the companyās...
418 Views
ECM Weekly (25 October 2020) - Ant Group, Lufax, JW Thera, Shimao Svcs, GDS Secondary, Nanofilm
Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs. This week...
737 Views